Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and third-quarter 2022 financial results.
- After a recent review of enrollment data that projected significant delays, Kronos Bio will discontinue the Phase 3 entospletinib trial and close enrollment in the fourth quarter of 2022.
- Kronos Bio remains on track to report pharmacokinetic (PK), pharmacodynamic (PD) and safety data, as well as the RP2D, from the Phase 1/2 study of KB-0742 in solid tumors in the fourth quarter of 2022.
- Kronos Bio is a biopharmaceutical company that is advancing two investigational compounds in clinical trials for patients with cancer.
- Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.